Jennison Associates’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,324,410
| Closed | -$45M | – | 591 |
|
|
2024
Q3 | $45M | Buy |
1,324,410
+321,325
| +32% | +$10.9M | 0.03% | 248 |
|
|
2024
Q2 | $37.1M | Buy |
1,003,085
+315,005
| +46% | +$11.7M | 0.02% | 260 |
|
|
2024
Q1 | $28.9M | Buy |
688,080
+668,002
| +3,327% | +$28M | 0.02% | 299 |
|
|
2023
Q4 | $796K | Sell |
20,078
-6,812
| -25% | -$270K | ﹤0.01% | 517 |
|
|
2023
Q3 | $740K | Sell |
26,890
-1,302,205
| -98% | -$35.8M | ﹤0.01% | 498 |
|
|
2023
Q2 | $45.1M | Sell |
1,329,095
-252,995
| -16% | -$8.58M | 0.04% | 202 |
|
|
2023
Q1 | $56.9M | Buy |
1,582,090
+26,772
| +2% | +$963K | 0.05% | 168 |
|
|
2022
Q4 | $69.3M | Buy |
1,555,318
+281,297
| +22% | +$12.5M | 0.07% | 149 |
|
|
2022
Q3 | $35.8M | Buy |
+1,274,021
| New | +$35.8M | 0.04% | 226 |
|
|
2014
Q4 | – | Sell |
-201,845
| Closed | -$39.2M | – | 718 |
|
|
2014
Q3 | $39.2M | Sell |
201,845
-10,312
| -5% | -$2M | 0.04% | 363 |
|
|
2014
Q2 | $51.9M | Sell |
212,157
-20,398
| -9% | -$4.99M | 0.05% | 320 |
|
|
2014
Q1 | $61.6M | Sell |
232,555
-32,899
| -12% | -$8.72M | 0.06% | 291 |
|
|
2013
Q4 | $96.4M | Sell |
265,454
-19,404
| -7% | -$7.05M | 0.09% | 197 |
|
|
2013
Q3 | $151M | Sell |
284,858
-26,645
| -9% | -$14.2M | 0.16% | 131 |
|
|
2013
Q2 | $72.9M | Buy |
+311,503
| New | +$72.9M | 0.08% | 229 |
|